Diabetes care
Home-use glucose monitoring for adults with diabetes.
FIBERSENSE – THE CxM COMPANY
Deep health data.
Powered by light.
FiberSense AG is advancing optical biosensing to transform how we understand and care for our health. Through FiberSense CGM, FiberSense PRO and Noovia, we are pursuing a bold vision: CxM, a new category of continuous monitoring that reaches beyond glucose.
OUR BRANDS
One foundation.
Specialised brands.
Our optical sensing technology powers distinct applications in diabetes care, professional healthcare and lifestyle – each designed for a specific audience, setting and opportunity.
THE CxM VISION
From CGM to CxM.
Defining a new category.
CxM is our vision for a new category of continuous multi-analyte monitoring. Building on our expertise in optical glucose sensing, we are developing capabilities to follow more biomarkers over time and reveal a richer picture of human health.
LACTATE
In Development
CORTISOL
In Development
ADDITIONAL
ANALYTES
ANALYTES
Future
KETONES
In Development
Additional analytes and applications require further development, validation and applicable regulatory clearances. Sensing fibre approx. 5 mm beneath the skin. Light effects illustrative and not to scale.
THE CxM DIFFERENCE
Built differently.
From the sensor up.
FiberSense replaces conventional electrochemical sensing with a proprietary fibre-optic photometric architecture. Light-based measurement, extended wear and reusable electronics create a platform designed to expand beyond glucose.
Photometric Sensing
Measures with light, not electrochemistry.
Extended Wear
Up to 28 days in the current FiberSense CGM application.
Interference Resistance
No relevant interference observed for common drugs and substances tested.
Reusable Electronics
A rechargeable detector designed to stay in use across sensor cycles.
CxM Ready
One sensing architecture with a development path beyond glucose.
Efficient by Design
Longer wear and reusable electronics mean less disposable hardware.
Measures glucose through changes in fluorescence at the sensing fibre.
Up to 28 days per sensor in the FiberSense CGM application.
No relevant interference observed for common drugs and substances tested.
Removable, rechargeable detector stays in use across sensor changes.
Optical sensing architecture with a development path beyond glucose.
Longer wear and reusable electronics mean less disposable hardware.
Clinical evidence relates to FiberSense glucose sensing. Patent figures refer to the group portfolio.
OUR CREDIBILITY
CE-marked
Class IIb
Paired clinical data points
10000
+
Granted and pending patents
100
+
Clinical evidence relates to FiberSense glucose sensing. Patent figures refer to the group portfolio.
WHO WE ARE
Medtech heritage.
Ambition beyond glucose.
Headquartered in Basel, Switzerland, with R&D and manufacturing in Germany, FiberSense brings together optical sensing expertise, medical-device development and commercial experience to advance continuous health monitoring.
BASEL, SWITZERLAND
Corporate Headquarters
GERMANY
Research, Development & Manufacturing
EYESENSE HERITAGE
Optical sensing expertise since 2006
CONNECT
Shape CxM with us.
We work with strategic partners, investors and exceptional talent to bring FiberSense technology into new markets, applications and care settings.
Partners
Bring FiberSense technology into new commercial, clinical and technology ecosystems.
Investors
Back a platform designed to scale across brands, markets and future analytes.
Careers
Join the team developing the next generation of continuous sensing.